Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce A Chabner

Showing results (121-130 of 139) with videos related to

Pageof 14
Sort By:
JCO Global Oncology|December 3, 2021
Accuracy of Pathologic Diagnosis in Patients With Lymphoma and Survival: A Prospective Analysis From BotswanaFallon E Chipidza, Mukendi K A Kayembe, Isaac Nkele, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2004
Prostate-specific antigen doubling time as a surrogate marker for evaluation of oncologic drugs to treat prostate cancerGary J Kelloff, Donald S Coffey, Bruce A Chabner, et al.
The Oncologist|April 19, 2002
Between parent and child: negotiating cancer treatment in adolescentsRichard T Penson, Paula K Rauch, Steve L McAfee, et al.
JAMA|November 4, 2004
Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trialsThomas G Roberts, Bernardo H Goulart, Lee Squitieri, et al.
International Journal of Radiation Oncology, Biology, Physics|October 14, 2015
A Roadmap for a New Academic Pathway for Global Radiation OncologyAdam C Olson, C Norman Coleman, Stephen M Hahn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2004
Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug developmentJohn W Park, Robert S Kerbel, Gary J Kelloff, et al.
Clinical Colorectal Cancer|March 18, 2004
Dihydropyrimidine dehydrogenase and thymidylate synthase polymorphisms and their association with 5-fluorouracil/leucovorin chemotherapy in colorectal cancerAndrew X Zhu, Thomas A Puchalski, Vincent P Stanton, et al.
The Oncologist|May 29, 2020
A Phase II Trial of Cabozantinib in Hormone Receptor-Positive Breast Cancer with Bone MetastasesJing Xu, Michaela J Higgins, Sara M Tolaney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 2, 2008
Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkersWyndham H Wilson, Kieron Dunleavy, Stefania Pittaluga, et al.
Theranostics|July 23, 2016
Holographic Assessment of Lymphoma Tissue (HALT) for Global Oncology Field ApplicationsDivya Pathania, Hyungsoon Im, Aoife Kilcoyne, et al.
Pageof 14

Showing results (121-130 of 139) with videos related to

Sort By:
Pageof 14
JCO Global Oncology|December 3, 2021
Accuracy of Pathologic Diagnosis in Patients With Lymphoma and Survival: A Prospective Analysis From BotswanaFallon E Chipidza, Mukendi K A Kayembe, Isaac Nkele, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2004
Prostate-specific antigen doubling time as a surrogate marker for evaluation of oncologic drugs to treat prostate cancerGary J Kelloff, Donald S Coffey, Bruce A Chabner, et al.
The Oncologist|April 19, 2002
Between parent and child: negotiating cancer treatment in adolescentsRichard T Penson, Paula K Rauch, Steve L McAfee, et al.
JAMA|November 4, 2004
Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trialsThomas G Roberts, Bernardo H Goulart, Lee Squitieri, et al.
International Journal of Radiation Oncology, Biology, Physics|October 14, 2015
A Roadmap for a New Academic Pathway for Global Radiation OncologyAdam C Olson, C Norman Coleman, Stephen M Hahn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2004
Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug developmentJohn W Park, Robert S Kerbel, Gary J Kelloff, et al.
Clinical Colorectal Cancer|March 18, 2004
Dihydropyrimidine dehydrogenase and thymidylate synthase polymorphisms and their association with 5-fluorouracil/leucovorin chemotherapy in colorectal cancerAndrew X Zhu, Thomas A Puchalski, Vincent P Stanton, et al.
The Oncologist|May 29, 2020
A Phase II Trial of Cabozantinib in Hormone Receptor-Positive Breast Cancer with Bone MetastasesJing Xu, Michaela J Higgins, Sara M Tolaney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 2, 2008
Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkersWyndham H Wilson, Kieron Dunleavy, Stefania Pittaluga, et al.
Theranostics|July 23, 2016
Holographic Assessment of Lymphoma Tissue (HALT) for Global Oncology Field ApplicationsDivya Pathania, Hyungsoon Im, Aoife Kilcoyne, et al.
Pageof 14